A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Last updated: March 26, 2025
Sponsor: ViiV Healthcare
Overall Status: Active - Not Recruiting

Phase

2

Condition

Hiv Infections

Treatment

rHuPH20

VH3810109

Cabotegravir

Clinical Study ID

NCT05996471
209639
  • Ages 18-70
  • All Genders

Study Summary

The study aims at evaluating the efficacy of VH3810109, dosed in accordance with the dosing schedule as either intravenous (IV) infusion or subcutaneous (SC) infusion with recombinant hyaluronidase (rHuPH20), in combination with cabotegravir (CAB) intramuscular (IM) dosed in accordance with the dosing schedule in virologically suppressed, Antiretroviral therapy (ART)-experienced adult participants living with HIV.

VH3810109 plus rHuPH20 plus Cabotegravir arm of the study has been discontinued based on preliminary results.

Eligibility Criteria

Inclusion

Inclusion criteria

Age

  1. Participant must be 18 to 70 years of age inclusive, at the time of signing theinformed consent. Type of Participant and Disease Characteristics

  2. Must be on uninterrupted current regimen for at least 6 months prior to Screening.Any prior switch, defined as a change of a single drug or multiple drugssimultaneously, must have occurred due to tolerability/safety, access tomedications, or convenience/simplification, and must NOT have been done fortreatment failure (HIV-1 RNA ≥200 c/mL). Acceptable stable - ARV regimens prior to Screening include at least one NRTI plus:

  • INI

  • NNRTI

  • Boosted PI (or atazanavir [ATV] unboosted)

  • Excludes current use of cabotegravir or fostemsavir The addition, removal, or switch of a drug(s) that has been used to treat HIV basedon antiretroviral properties of the drug constitutes a change in ART with thefollowing limited exceptions:

  • Historical changes in formulations of ART drugs or booster drugs will notconstitute a change in ART regimen if the data support similar exposures andefficacy, and the change must have been at least 3 months prior to Screening.

  • Historical maternal perinatal use of an NRTI when given in addition to anongoing HAART will not be considered a change in ART regimen.

  • A change in dosing scheme of the same drug from twice daily to once daily willnot be considered a change in ART regimen if data support similar exposures andefficacy.

  1. Documented evidence of at least two plasma HIV-1 RNA measurements <50 c/mL in the 12months prior to Screening: one within the 6 to 12-month window, and one within 6months prior to Screening;

  2. Plasma HIV-1 RNA <50 c/mL at Screening;

  3. Screening CD4+ T-cell count ≥350 cells/mm3: Weight

  4. Body weight >=50 kg to <=115 kg. Sex

  5. Male and/or female Contraceptive use by men or women should be consistent with localregulations regarding the methods of contraception for those participating inclinical studies, assuring minimal contraception requirements noted below.

All participants participating in the study should be counselled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g. male condom) and on the risk of HIV transmission to an uninfected partner.

  1. Participants who are female at birth are eligible to participate if at least one ofthe following conditions applies:
  • Not pregnant or breastfeeding and at least one of the following conditionsapplies:

  • Is not a participant of childbearing potential (POCBP). OR

  • Is a POCBP and using an acceptable contraceptive method during theintervention period (at a minimum until after the last dose of studyintervention). The investigator should evaluate the effectiveness of thecontraceptive method in relationship to the first dose of studyintervention.

  • A POCBP must have a negative highly sensitive pregnancy test (urine or serum asrequired by local regulations) on Day 1, prior to the first dose of studyintervention.

  • If a urine test cannot be confirmed as negative (e.g., an ambiguous result),a serum pregnancy test is required. In such cases, the participant must beexcluded from participation if the serum pregnancy result is positive.
  • The investigator is responsible for review of medical history, menstrualhistory, and recent sexual activity to decrease the risk for inclusion of aPOCBP with an early undetected pregnancy. QTc 8. QTc Interval <450 msec. Phenotypic Sensitivity 9. Viral phenotypic sensitivity to VH3810109 based on IC90 of <=2 ug/mL and a Maximum Percent Inhibition >98% using the Monogram PhenoSense mAbAssay on sample obtained at a screening visit. Informed Consent 10. Capable of giving signed informed consent which includescompliance with the requirements and restrictions listed in the informed consentform (ICF) and in this protocol.

Exclusion

Exclusion Criteria: Medical conditions:

• Participants who are pregnant, breastfeeding, plan to become pregnant orbreastfeed during the study

  • Participants having skin disease or disorder (i.e. infection, inflammation,dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy,urticaria) or tattoo overlying potential injection sites which may interferewith interpretation of injection site reactions or administration of VH3810109or CAB

  • Participant has a gluteal implant/enhancement (including fillers) overlying thegluteus area or any other area which may significantly interfere withinterpretation of injection site reactions

  • Participants with known history of cirrhosis with or without viral hepatitisco-infection

  • Participants with ongoing or clinically relevant pancreatitis

  • Untreated syphilis infection (positive rapid plasma reagin (RPR) at screening)without documentation of treatment. Participants who are at least 7 days postcompleted treatment are eligible if recruitment is open

  • Prior receipt of licensed or investigational HIV monoclonal antibody

  • Any evidence of an active Centers for Disease Control and Prevention (CDC)Stage 3 disease except cutaneous Kaposi's sarcoma not requiring systemictherapy. Historical or current CD4 cell counts less than 200 cells/mm^3 are notexclusionary

  • History of sensitivity to any of the study medications or their components ordrugs of their class, or a history of drug or other allergy that, in theopinion of the investigator or Medical Monitor, contraindicates theirparticipation

  • Any condition which, in the opinion of the investigator, may interfere with theabsorption, distribution, metabolism or excretion of the study drugs, cART orrender the participant unable to take oral medication

  • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening

  • Previous exposure to cabotegravir

  • Participant enrolled in a prior or concurrent clinical study that includes adrug intervention within the last 30 days

  • Participants with ongoing chronic hepatitis B virus infection

  • Participants with hepatitis C co-infection

  • Participants who in the investigator's judgment, pose a significant suicidalityrisk

  • Contraindications, as per the current Prescribing Information for cabotegravir.

  • Previous hypersensitivity reaction to cabotegravir or

  • Contraindicated co-administered drugs:

  • Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin

  • Antimycobacterials: Rifabutin, rifampin, rifapentine

  • Glucocorticoid (systemic): Dexamethasone (more than a single-dosetreatment)

  • Herbal product: St John's wort (Hypericum perforatum) Prior/Concomitant Therapy:

• Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.

  • Previous exposure to cabotegravir.

  • Treatment with any of the following agents within 60 days of screening: -radiation therapy; -cytotoxic chemotherapeutic agents; -any systemic immune suppressant.

  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half lives of the test agent, or twice the duration of the biological effectof the test agent, whichever is longer, prior to the first dose of studymedication.

  • Current or anticipated need for chronic anti-coagulants.

  • Participants receiving any prohibited medication and who are unwilling orunable to switch to an alternate medication. Prior/Concurrent Clinical Study Experience • Participant enrolled in a prior orconcurrent clinical study that includes a drug intervention within the last 30 days. Diagnostic Assessments

• Any acute laboratory abnormality at Screening, which, in the opinion of theinvestigator, would preclude the participants inclusion in the study of aninvestigational compound.

• Any evidence of viral resistance based on the presence of any major cabotegravirresistance-associated mutation [IAS-USA, 2022] in any historic resistance testresult.

• Any verified Grade 4 laboratory abnormality with the exception of Grade 4triglycerides or lipid abnormalities. A single repeat test is allowed during theScreening period to verify a result.

• Alanine aminotransferase (ALT) >=3 times the upper limit of normal (ULN)

  • Creatinine clearance of <50 mL/min/1.73 m^2 via using the refitted,race-neutral Chronic Kidney Disease Epidemiology Collaboration (CKD-EPIcr_R)method.

  • PT >=Grade 2 (>=1.25 ULN). A single repeat test is allowed during the Screeningperiod to verify a result. Other Exclusion Criteria

• To assess any potential impact on participant eligibility with regard to safety,the investigator must refer to the IB and supplements, approved product labels,and/or local prescribing information for detailed information regarding warnings,precautions, contraindications, AEs, drug interactions, and other significant datapertaining to the study drugs.

Study Design

Total Participants: 135
Treatment Group(s): 4
Primary Treatment: rHuPH20
Phase: 2
Study Start date:
August 17, 2023
Estimated Completion Date:
January 17, 2029

Connect with a study center

  • GSK Investigational Site

    San Juan, 909
    Puerto Rico

    Site Not Available

  • GSK Investigational Site

    Birmingham, Alabama 35294
    United States

    Site Not Available

  • GSK Investigational Site

    Bakersfield, California 93301
    United States

    Site Not Available

  • GSK Investigational Site

    Los Angeles, California 90069
    United States

    Site Not Available

  • GSK Investigational Site

    Palm Springs, California 92262
    United States

    Site Not Available

  • GSK Investigational Site

    Sacramento, California 95825
    United States

    Site Not Available

  • GSK Investigational Site

    San Francisco, California 94110
    United States

    Site Not Available

  • GSK Investigational Site

    New Haven, Connecticut 06510
    United States

    Site Not Available

  • GSK Investigational Site

    Washington, District of Columbia 20007
    United States

    Site Not Available

  • GSK Investigational Site

    Fort Lauderdale, Florida 33308
    United States

    Site Not Available

  • GSK Investigational Site

    Fort Pierce, Florida 34982
    United States

    Site Not Available

  • GSK Investigational Site

    Miami, Florida 33133
    United States

    Site Not Available

  • GSK Investigational Site

    Orlando, Florida 32803
    United States

    Site Not Available

  • GSK Investigational Site

    Pensacola, Florida 32504
    United States

    Site Not Available

  • GSK Investigational Site

    Sarasota, Florida 34237
    United States

    Site Not Available

  • GSK Investigational Site

    Vero Beach, Florida 32960
    United States

    Site Not Available

  • GSK Investigational Site

    West Palm Beach, Florida 33401
    United States

    Site Not Available

  • GSK Investigational Site

    Decatur, Georgia 30033
    United States

    Site Not Available

  • GSK Investigational Site

    Chicago, Illinois 60611
    United States

    Site Not Available

  • GSK Investigational Site

    Boston, Massachusetts 02115
    United States

    Site Not Available

  • GSK Investigational Site

    Springfield, Massachusetts 01105
    United States

    Site Not Available

  • GSK Investigational Site

    Southfield, Michigan 48075
    United States

    Site Not Available

  • GSK Investigational Site

    Columbia, Missouri 65212
    United States

    Site Not Available

  • GSK Investigational Site

    Newark, New Jersey 07102
    United States

    Site Not Available

  • GSK Investigational Site

    Albuquerque, New Mexico 87109
    United States

    Site Not Available

  • GSK Investigational Site

    Santa Fe, New Mexico 87505
    United States

    Site Not Available

  • GSK Investigational Site

    Bronx, New York 10467
    United States

    Site Not Available

  • GSK Investigational Site

    Manhasset, New York 11030
    United States

    Site Not Available

  • GSK Investigational Site

    New York, New York 10461
    United States

    Site Not Available

  • GSK Investigational Site

    Chapel Hill, North Carolina 27599
    United States

    Site Not Available

  • GSK Investigational Site

    Greensboro, North Carolina 27401-1209
    United States

    Site Not Available

  • GSK Investigational Site

    Cincinnati, Ohio 45267
    United States

    Site Not Available

  • GSK Investigational Site

    Portland, Oregon 97239
    United States

    Site Not Available

  • GSK Investigational Site

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • GSK Investigational Site

    Nashville, Tennessee 37208
    United States

    Site Not Available

  • GSK Investigational Site

    Austin, Texas 78705
    United States

    Site Not Available

  • GSK Investigational Site

    Dallas, Texas 75246
    United States

    Site Not Available

  • GSK Investigational Site

    El Paso, Texas 79902
    United States

    Site Not Available

  • GSK Investigational Site

    Houston, Texas 77030
    United States

    Site Not Available

  • GSK Investigational Site

    Milwaukee, Wisconsin 53226
    United States

    Site Not Available

  • GSK Investigational Site

    Watertown, Wisconsin 53226
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.